Regeneron Sees Demand for Its Covid Therapy as Vaccinations Drop
(Bloomberg) -- Demand for Regeneron Pharmaceuticals Inc.'s Covid-19 antibody therapy will continue for the long term, with a great many people in the U.S. unwilling or unable to be vaccinated.
That was the message from Regeneron's Chief Executive Officer Leonard Schleifer during a conference call Thursday. The Tarrytown, New York-based company is seeking to expand authorization of the antibody cocktail after the U.S. Food and Drug Administration in November cleared it for emergency use in early-stage Covid patients at risk of developing severe disease.
The updates to the authorization would allow the antibody cocktail to be administered at a lower dose and to be used for Covid-19 prevention. The company said on the earnings call that it anticipates FDA action on the lower dose in the next several weeks.
“We see an ongoing global need for treatment and chronic prevention of Covid disease,” Schleifer said on the earnings call. “Despite high rates of vaccination, it's estimated that tens of millions will remain unvaccinated in the U.S. alone. And of those who are vaccinated, significant numbers will not mount a protective response, such as those who are immunocompromised or immunosuppressed.”
Regeneron's shares rose 2.3% to $493.42 at 11:16 a.m. in New York trading.
The Regen-cov drug, which initially received emergency use authorization in November, recorded $262 million in U.S. sales in the first quarter, the company reported Thursday. Earnings per share and revenue topped Wall Street estimates. Overall, the company reported revenues of $2.5 billion, up 38% from a year earlier.
The antibody cocktail is part of a class of therapies that were widely hailed for their effectiveness, though the drugs have been slow to be widely adopted because they are difficult to administer.
Schleifer on Thursday called for wider adoption of the therapy.
“Clearly, we have to better understand why a drug that has demonstrated overwhelming evidence for its ability to reduce hospitalizations or death by 70%, is in ample supply, has been endorsed by the NIH, has been authorized under an EUA by the FDA and is free of charge to patients, is not being taken full advantage of,” the CEO said.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.